Objective Drug interactions resulting in adverse drug reactions (ADRs) represent a major health problem both for individuals and the community. Despite this, limited information is reported in the literature on the drug interaction categories responsible for causing ADRs. In the study reported here, we investigated the drug combinations most frequently co-reported as interacting in the WHO Global Individual Case Safety Report (ICSR) database, VigiBase, and categorised these according to the drug interaction mechanism. Methods Reports in which drug combinations were coreported as interacting in at least 20 reports in VigiBase during the past 20 years were included in the study. Each drug combination was reviewed in the literature to identify the mechanism of interaction and subsequently classified as pharmacodynamic and/or pharmacokinetic reaction. Report characteristics were also analysed. Results A total of 3766 case reports of drug interactions from 47 countries were identified. Of the 123 different drug combinations reported, 113 were described in the literature to interact. The mechanism of the drug interaction was categorised as pharmacodynamic (46 combinations; 41%), pharmacokinetic (28; 25%), a combination of both types (18; 16%) and unidentified (21; 19%). Pharmacodynamic drug interactions primarily concerned pharmacological additive effects, whereas enzyme inhibition was the most frequent pharmacokinetic interaction. The combinations reviewed primarily implicated drugs such as warfarin, heparin, carbamazepine and digoxin. Conclusions Drug interactions reported in globally collected ADR reports cover both pharmacodynamic, specifically additive pharmacological effects, and pharmacokinetic mechanisms primarily accredited to the inhibition of hepatic cytochrome P450 enzymes. These ADR reports often concern serious threats to patients' safety and are particularly related to the use of high risk drugs such as warfarin and heparin.
Introduction
Polypharmacy increases the complexity of therapeutic management and thereby the risk of clinically important drug interactions, which may result in adverse drug reactions (ADRs) or reduced therapeutic effect in individuals [1] . However, the magnitude of ADRs related to drug interactions that has been reported in the literature is inconsistent, probably reflecting the variety of settings and populations studied. A recently published study based on individual case safety reports (ICSRs) found that 22% of patients exposed to a potential drug interaction experienced an associated ADR [2] , while in specific hospital settings, drug interactions have been reported to cause up to 59% of all ADRs [3, 4] .
A large proportion of potentially clinically significant drug interactions are reported to occur as a result of alterations in the hepatic drug metabolism, mostly in the activity of cytochrome P450 (CYP) enzymes, such as CYP3A4, CYP2C9, CYP2C19, CYP1A2 and CYP2D6, glucuronidation and drug transporters, such as Pglycoprotein. Hence, pharmacokinetic properties and related drug interactions are often well supported in clinical studies referred to in the SPC (Summary of the Product Characteristics) texts and specific drug interaction references. While those pharmacodynamic interactions that are apparent from the main pharmacological action of the drugs are often expected to be understood by prescribing physicians [5] , are often undersupplied in drug reference texts unless the drug combination may result in serious toxicity, such as prolonged QT interval.
Adverse effects due to drug interactions are a common and-to a large extent-preventable health care issue. As ICSRs are reflections of drug-related problems within the health care sector, these reports can provide insight into which drug interactions that are of particular concern and their characteristics. However, few studies have actually examined the drug interaction categories responsible for causing ADRs. Subsequently, the aim of this study was to explore ICSRs on drug combinations most frequently coreported as interacting that have been collected in the World Health Organisation (WHO) Global ICSR Database, VigiBase, and to categorise drug combinations according to their drug interaction mechanism.
Methods and data
Reports in which drug combinations were co-reported as being suspected of interacting in at least 20 reports in VigiBase during the past 20 years were included in the study. Each drug combination was reviewed in the literature for the mechanism of interaction and classified according to pre-defined categories. To further characterise these suspected drug interactions reported to VigiBase, we also assessed information on the date of the report, gender, reporter and country of origin.
Data source
The WHO Programme for International Drug Monitoring was initiated in 1968 to detect previously unknown drug safety problems and still remains as one of the central elements for global safety surveillance [6] . To maintain the programme's operation, ICSRs (also referred to as spontaneous reports of suspected ADRs and synonymously referred to as reports in this paper) are collected in the WHO Global ICSR database, VigiBase [7] . The reports are compiled on a national basis by the individual member countries (n=104) of the WHO Programme for International Drug Monitoring and then forwarded to, processed and stored in VigiBase.
Each report contains at least one drug, an ADR, the country submitting the report and an identification number. Drugs listed on the reports are assigned a rating of 'suspected' (drugs suspected of being related to the ADR, but the ADR is not explicitly due to a drug interaction), 'interacting' (if an ADR is suspected of being related to a drug interaction between two or more drugs) or 'concomitant' (drugs used concurrently but not suspected by the reporter to have caused the adverse event). The information contained in the reports is provided by a primary reporter or through a second evaluation performed by the National Centre. The individuals providing the information listed on the reports are referred to as the reporter. The reports also contain additional information, such as age, gender, type of report (spontaneous, study report), etc.
Classification Drug interaction mechanisms were categorised into two main groups: pharmacokinetic and pharmacodynamic [8, 9] . Pharmacokinetic interactions were further divided into mechanistic subgroups with additional sub-classifications given in brackets: (1) absorption (changes in gastrointestinal pH, changes in gastrointestinal motility, chelation and adsorption, damage to gastrointestinal tract, induction or inhibition of drug transport proteins, reduction of gut flora); (2) distribution (protein-binding 'displacement', induction or inhibition of drug transport proteins); (3) metabolism (hepatic uptake, such as induction or inhibition of drug transport proteins, enzyme induction, enzyme inhibition); (4) excretion (hepatic secretion into the bile, such as induction or inhibition of drug transport proteins, changes in urinary pH, active tubular secretion, such as induction or inhibition of drug transport proteins). Pharmacodynamic interactions were initially divided into two categories: direct effect at receptor function and interference with a biological or physiological process. In a pilot phase, we discovered that many of the pharmacodynamic drug combinations were associated with additive pharmacological effects rather than synergistic effects. Additive pharmacological effects were therefore included as a subgroup of pharmacodynamic mechanisms, even though these are not covered by the general definition of a drug interaction (namely, "pharmacological or clinical response of one drug is changed in the presence of another drug" [CR8]) as its effects are not changed. Pharmacodynamic interactions were divided into the following subgroups: 1) direct effect at receptor function, 2) interference with a biological or physiological control processes and 3) additive/opposed pharmacological effect.
Those drug combinations that were established to interact but with an unidentified mechanism were listed as 'unidentified mechanism'. Drug combinations for which negative results for a potential drug interaction were concluded were noted as 'no interaction'. Drug combinations without published information of a possible interaction were classified as 'unknown in the literature'.
Analyses
Reports in which drug combinations were co-reported as interacting in at least 20 reports in VigiBase during the past 20 years were included in the study. To characterise this subset of suspected drug interactions, we retrieved and analysed information on the date of report, gender, reporter and country of origin. Selected drug combinations were reviewed in the literature for the mechanism of interaction and classified according to the pre-defined categories. The following literature sources were reviewed for interaction mechanisms in the order given: (1) Stockley's drug interactions [10] , (2) FASS (Swedish drug compendium) [11] , (3) DrugDex [12] and (4) PubMed [13] . When the information in Stockley's drug interactions, FASS for health care professionals and DrugDex was consistent, no further literature search in PubMed was made. For those combinations where more than one mechanism was suggested for the interaction, all mechanisms of interaction were listed. To clarify the involvement in each mechanism, we classified drugs as object (the affected drug) and precipitant (induced the interaction) [14] . Both drugs were noted as object in cases where the interaction was documented to result in an additive or synergistic effect. Additional information on each mechanism was extracted from the literature: (1) expected outcome specified as toxic effect or reduced efficacy; (2) type of pharmacological effect noted as additive, synergistic or antagonistic for pharmacodynamic interactions.
Supplementary analyses
As a drug may be involved in several clinically important mechanisms, all mechanisms found for the drug in the literature review were summarised. To investigate if the reported response (based on reports in VigiBase) corresponded to the expected outcome of verified drug interactions, we reviewed the most commonly reported ADR terms [15] for a drug combination.
Results
From January 1990 to February 2010, 4,149,345 reports were entered in VigiBase, of which 18,409 included reports of two drugs interacting. During the study period, 123 drug combinations were co-reported as interacting in at least 20 reports (in total 3766 reports) and thus included in the analysis. The analysis included reports from 47 countries, with the majority (67%) originating from Europe; this contrasts with the general distribution of reports in VigiBase whereof the USA represents 50%. When excluding reports lacking gender specification, reports on females (52%) were slightly more common than those on males (48%), which is also different from the general distribution of reports in VigiBase where 60% concern females. In total, 83% of the reports were submitted from health care professionals [physicians (78%), pharmacists (4%), nurses and dentists (1%)]. This also contrasts to VigiBase in general, where 63% are received from health care professionals.
Mechanisms
Of the 123 drug combinations reviewed, 113 were verified in the literature as interactions. A total of 65 pharmacodynamic and 68 pharmacokinetic mechanisms were reported in the literature (Table 1) . Among the drug combinations studied, the most commonly reported mechanisms were interactions via additive pharmacological effects and inhibition of the metabolic pathway. Of the interactions directly associated to a specific enzyme, CYP3A4 and CYP2C9 were particularly frequent, accounting for 42 and 24% of interactions, respectively. Other enzymes reported as being involved in these drug interactions were CYP1A2, CYP2B6, CYP2C19, CYP2C8 and epoxide hydrolase. For 40 drug combinations more than one mechanism was accredited for the interaction. Whereas some were purely pharmacokinetic in nature, as for digoxin and clarithromycin, involving drug distribution (induction or inhibition of drug transport proteins [10, 12] and reduction of gut flora [10] [11] [12] ) and excretion (changes in renal blood flow [10] [11] [12] ), others were a mix of pharmacodynamic and pharmacokinetic mechanisms, as for warfarin and celecoxib that functions via additive pharmacological effects [10, 11] and enzyme inhibition [10, 12] (Table 2 ). For the reviewed drug combinations, protein-binding displacement, inhibition of drug transport proteins and inhibition of the gut flora were often described as only minor mechanisms and rarely reported as being exclusively responsible for the drug interaction.
A review of the unique nature of the 113 verified interactions revealed that 46 (41%) were purely pharmacodynamic interaction, 28 (25%) were pharmacokinetic interactions and 18 (16 %) were a mix of both types. For 11 either purely pharmacodynamic and pharmacokinetic interactions, additional mechanisms, yet unidentified, were proposed, as the main mechanism of action was assumed not to explain the interaction's total effect. In addition, 21 (19%) drug combinations [e.g. selective serotonin re-uptake inhibitors (SSRIs) with lithium, or warfarin with tramadol or warfarin with norfloxacin] were reported to interact although no detailed description of a mechanism was reported; however, the interactions have been acknowledged in case reports or case series.
Reported characteristics
The reviewed combinations primarily involved wellestablished drugs, i.e. drugs that have been marketed for more than 10 years. Antithrombotic agents were most frequently reported of the drugs showing pharmacodynamic interactions (Table 3) , while pharmacokinetic interactions involved a range of drugs that inhibit or compete for hepatic CYP enzymes. The substantial influence of antithrombotic agents in frequently reported pharmacodynamic interactions were reflected by the overall ADR pattern reported for pharmacodynamic interactions in VigiBase (ordered by total number of reports): gastrointestinal haemorrhage, haematoma, melaena and decreased prothrombin level. In contrast, the variety of drugs involved in pharmacokinetic interactions reflected the range of ADRs reported but also alterations in therapeutic effect (ordered by total number of reports): increased drug level, decreased prothrombin level, rhabdomyolysis and increased therapeutic response. ADRs reported for verified interactions were well associated with the expected effect of the object drug (Table 2) as shown by the numerous reports of warfarin-related effects [increased international normalised ratio and or decreased prothrombin level] during concurrent use of roxithromycin and miconazole, or the risk of statin-induced rhabdomyolysis during the concurrent use of gemfibrozil.
Non-interacting drug combinations
For ten drug combinations, the literature did not include information of a possible interaction. Among these noninteracting drug combinations were: (1) warfarin and digoxin; (2) three drug combinations involving drugs used in standard tuberculosis treatment regimens (ethambutol with pyrazinamide, ethambutol with rifampicin and isoniazid with pyrazinamide); (3) a vitamin K antagonist, Reduction of gut flora [10] [11] [12] Therapeutic response (124) Changes in renal blood flow [10] [11] [12] Nausea, bradycardia (6) Gemfibrozil Cerivastatin 113 Hepatic uptake -induction or inhibition of drug transport proteins [27] [28] [29] Rhabdomyolysis (89) Enzyme inhibition [27] [28] [29] [30] Myalgia (26) Additive/opposed pharmacological effect [27] Renal failure acute, blood CPK Valproic acid Lamotrigine 111 Drug metabolism Drug interaction (18) Enzyme inhibition [10] [11] [12] Stevens-Johnson syndrome, pyrexia (14) Acetylsalicylic acid Heparin 102 Additive/opposed pharmacological effect [10] [11] [12] Haematoma (24) Anaemia (16) Cerebral haemorrhage (14) Acetylsalicylic acid Enoxaparin 97 Additive/opposed pharmacological effect [10] [11] [12] Haematoma (29) Anaemia (26) Melaena (12) Acetylsalicylic acid Diclofenac 93 Additive/opposed pharmacological effect [10] [11] [12] Gastrointestinal haemorrhage (44)
Unidentified mechanism [10, 12] Melaena (29) Abdominal pain (13) Warfarin Roxithromycin 89 Enzyme inhibition [10, 12, 32] Decreased prothrombin level (47)
Unidentified mechanism [10, 32] Increased INR (25) Haematuria (7) Isoniazid Rifampicin 75 Enzyme induction [10, 12] Nausea (9) Jaundice, hepatitis (8) Digoxin Furosemide 71 Interference with a biological or physiological control process [10] [11] [12] Vomiting (21) Bradycardia (18) Drug toxicity, increased drug level (16) Spironolactone Furosemide 71 Additive/opposed pharmacological effect [11] Renal failure acute (30) Hyperkalaemia (16) Hyponatraemia (15) Warfarin Miconazole 69 Enzyme inhibition [10] [11] [12] Prothrombin level dec. (22) Increased INR (16) Haematuria (13) Warfarin Celecoxib 60 Enzyme inhibition [10, 12] Prothrombin level dec. (30) Additive/opposed pharmacological effect [10, 11] Increased INR (9) Purpura (5) Acetylsalicylic acid Fluindione 59 Additive/opposed pharmacological effect [10] Anaemia (24) Melaena (15) Decreased prothrombin level, haematoma (12) ICSRs, Individual case safety report; ADR, adverse drug reaction; INR, international normalised ratio; CPK, creatine phosphokinase Eur J Clin Pharmacol (2011) 67:633-641fluindione, with various agents (amiodarone, ceftriaxone, ciprofloxacin, fluconazole and ofloxacin; with all reports submitted from France) (4) acetylsalicylic acid (ASA) with abciximab, whereas the drug's antithrombotic effects are used in combination for patients undergoing percutaneous coronary intervention [11] .
Discussion
The results of study demonstrated that the scope of drug interactions reported on globally collected ADR reports is broad and involves interactions of both a pharmacokinetic, with the inhibition of hepatic CYP enzymes being the foremost mechanism, and pharmacodynamic, primarily as additive pharmacological effects, nature. The latter is particularly noteworthy since pharmacodynamic interactions have been reported to have less clinical impact than pharmacokinetic interactions [5] . Moreover, ICSRs of suspected drug interactions often concern serious threats to patients' safety, particularly those related to the usage of high risk drugs, such as warfarin and heparin [16, 17] . Even though the spontaneous reporting system is a cornerstone of the early detection of previously unknown single drug-single ADR combinations [18] , there is a clear over-representation of established associations. We deliberately used this phenomenon when selecting drug combinations (inclusion criteria ≥20 reports) to identify drug interaction categories reported in ICSRs. A range of mechanisms was reported, and the scrutinised combinations were often the expression of more than one mechanism. CYP3A4 was the most commonly reported metabolic pathway in this subset of established associations, which was expected given its general involvement in drug metabolism. The proportion of CYP2C9 (24%) interactions was slightly higher than expected, but such interactions can also be explained by the numerous drug combinations involving warfarin. Enzyme inhibition was more common than enzyme induction in this subset, possibly due to the following reasons: (1) its general occurrence; (2) induction more rarely leads to an effect that has clinical impact; (3) enzyme inhibition is more easily associated to drug use as its ADR response occurs more rapidly [8, 9] .
Drug combinations not reported in the literature, which in general are more interesting for their signalling value [19] , can be explained on the basis of common drug therapies, whereas the individual drugs used in the combination are likely to interact with a range of other drugs (e.g. digoxin-warfarin, ASA-abciximab and drug combinations involving drugs used in standard tuberculosis regimens driven by the fact that rifampicin induces the metabolism of isoniazid) or reflect a lack of information in the international literature (as for the vitamin K antagonist, fluindione, for which several of the suspected interacting agents are known to interact with the more widely used vitamin K antagonist, warfarin [12] ).
This subset primarily included well-established drugs, as expected, since information on well-established drugs increases over time. Even though we focused on wellknown drug interactions in this analysis, previous reports have shown that there is a continuous need for monitoring such drugs as new problems, such as drug interactions related to the concurrent use of new drugs, emerge over time [20] [21] [22] . This point is also emphasised in other reviews of drug safety issues which to a large extent concerns well established drugs [23, 24] .
The reporting patterns for our subset of reports differ from the general reporting patterns found in VigiBase in two areas: (1) drug interactions were reported by a higher percentage of health care professionals; (2) reports on females were less frequent [25] . A higher rate of reports from health care professionals was expected as greater pharmacological knowledge is required to understand the more complex character of having more than one drug associated to the adverse outcome. In terms of gender distribution, Leone et al. found a similar result, where the proportions of potential interactions were greater for females, although men were more likely to experience an ADR related to a drug interaction [2] . However, given the nature of the data and the small set of drug interactions used in this analysis, disparities for gender in terms of experiencing drug interactions need to be subjected to further investigation.
The aim of this descriptive analysis was not to present the frequency of mechanisms for drug interactions outside this subset or the frequency of these drug combinations in VigiBase related to their background reporting or outside the database. However, it is possible that certain mechanisms are more frequently identified and, therefore, that certain drug combinations more frequently reported or, vice versa, that published data on some mechanisms, such as transport proteins, are more limited and these combinations are therefore less well represented in the subset.
In addition, VigiBase is heterogeneous with respect to the origin of data and level of suspicion, such that the assignment of drugs related to ADRs varies between member countries. For example, drugs involved in a drug interaction may be assigned as interacting or as suspected; in the case of the latter, the suspected drug interaction may then be noted in the case narratives or as an ADR term. However, these notations lack assignment to the specific drugs involved in the interaction as many more drugs may be listed as suspected on the individual case report. Subsequently, there is a clear under-reporting of drug For some interactions the mechanism was given on a general level without further specification: excretion (furosemide, amiodaronem digoxin, amiodarone); metabolism (carbamazepine, valproic acid); pharmacodynamic interaction (gemfibrozil, simvastatin). All of these were single occurences for these mechanisms, with the exception of valproic acid for which interactions were reported twice to be involved in metabolism interactions listed in the drug assignment in VigiBase, which results in a selection bias of the drug combinations included in this survey. However, this is not necessarily a problem as the reports in this analysis were received from a variety of countries. Increased reporting related to increased publicity is one of the general limitations of the ADR surveillance system, and this may have amplified further differences in assigning drugs as interacting in an individual case report [26] or could have led to increased reporting and hence inclusion in this survey. Despite the fact that adverse effects due to drug interactions are common, there has only been limited application of ICSRs for the early discovery of drug interaction signals. The results of the analysis reported here contributes to our knowledge of those drug interactions that are of particular concern and their respective mechanism of action. Overall, increased knowledge of the problems of such drug interactions is needed to be able to appropriately identify and manage any potential associated risk, with the ultimate aim of preventing such interactions during the early stage of prescribing and/or monitoring them closely.
Conclusion
Drug interactions reported on globally collected ADR reports covers both pharmacodynamic, specifically additive pharmacological effects, and pharmacokinetic mechanisms, primarily via CYP inhibition in the liver. These ADR reports often concern serious threats to patients' safety, particularly those related to the usage of high risk drugs, such as warfarin and heparin, and other well-established agents. Finally, drug interactions reported post-marketing do not only involve problems related to the drugs' pharmacological action but also to how the drugs are used.
